HeartBeam Q4 net loss widens

Overview

• U.S. cardiac monitoring tech firm's Q4 and full yr net loss widened vs prior yr

• Company received FDA clearance for cable-free 12-lead ECG synthesis software in Dec 2025

• HeartBeam began limited commercial launch and signed first commercial partnership with ClearCardio

Outlook

• Company plans broader expansion across multiple U.S. geographies following initial rollout

Result Drivers

• Research and development expenses for the fourth quarter of 2025 were $3.4 million, compared to $2.9 million for the fourth quarter of 2024

• INCREASED R&D SPENDING - Higher research and development expenses driven by new product development, including extended-wear ECG patch and AI-ECG algorithms

• Cash and cash equivalents totaled $4.4 million as of December 31, 2025, as compared to $2.4 million at December 31, 2024

Company press release: ID:nBw8Qmjwza

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Heartbeam Inc is $4.75, about 249.3% above its March 11 closing price of $1.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.